Evidence map›Paper›PMID 37369490›Full record

ReviewIn vivo (Athens, Greece)

Reclassification of Splicing Gene Variants in Hereditary Cancer: Cases Report and Literature Review.

Dimitra Bouzarelou, Konstantinos Agiannitopoulos, Georgios N Tsaousis, Eirini Papadopoulou, George Nasioulas

Open access · diamondAbstract readCase ReportsReview
In one paragraph

Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dimitra BouzarelouGenekor Medical S.A, Athens, Greece.
Konstantinos AgiannitopoulosGenekor Medical S.A, Athens, Greece kagiannitopoulos@genekor.com.
Georgios N TsaousisGenekor Medical S.A, Athens, Greece.
Eirini PapadopoulouGenekor Medical S.A, Athens, Greece.
George NasioulasGenekor Medical S.A, Athens, Greece.
Athens Medical Center · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternative splicing (AS), a crucial cellular process, is a source of transcriptomic expansion and protein variability. Its contribution to cancer development and progression among a vast repertoire of human diseases, is highlighted lately and is under extensive investigation. In this review, the relative recent aspects of AS as a hallmark of cancer are described. In parallel, the importance of the identification of splicing-related variants through next-generation sequencing technologies is discussed. Cancer therapy and the management of patients and their families can highly benefit by the classification of these variants.

Indexed as

Genetic Predisposition to DiseaseNeoplasmsAlternative SplicingHigh-Throughput Nucleotide SequencingHumansAlternative splicinghereditary cancernext-generation sequencing (NGS)reviewRNA analysis

Identifiers

PMID37369490
PMCPMC10347938
OpenAlexW4382344566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.